JKS

Pomerantz LLP is investigating JinkoSolar for potential securities fraud following significant stock price declines. The company reported a $214.5 million GAAP loss in Q4 2025 due to a $200+ million impairment charge that contradicted prior management statements.

In Q2 2026, JinkoSolar missed revenue and earnings estimates with gross margins collapsing to 4.2% from 8.3%, attributed to declining solar prices and weak Chinese demand. The stock fell approximately 12% on each disclosure date.

T1 Energy is building a vertically integrated U.S. solar supply chain spanning polysilicon, wafers, cells, and modules. The company operates G1_Dallas for module production and is developing G2_Austin, a 2.1 GW solar-cell facility expected to begin production in Q1 2027.

T1 acquired Evervolt's solar patents including TOPCon technology for $135 million and has secured domestic sourcing agreements with Hemlock Semiconductor and Corning. The company trades at a discount to industry peers with strong earnings growth projections.

Pomerantz LLP announced investigations into potential securities fraud and unlawful business practices at Stitch Fix, JinkoSolar, and America's Car-Mart. Stitch Fix's stock fell 21.63% following disappointing Q4 2026 earnings with declining active clients and net losses.

Pomerantz LLP announced investigations into securities fraud claims against SELLAS Life Sciences, JinkoSolar, and Stitch Fix. The investigation into SELLAS focuses on delayed release of phase 3 clinical trial results for Galinpepimut-S, which triggered an 13.15% stock price decline on August 28, 2026.

Pomerantz LLP announced investigations into potential securities fraud at Rent the Runway following the company's September 11, 2026 earnings report, which revealed a 3.8% year-over-year decline in active subscribers, disappointing Q3 guidance, and a dilutive capital raise. The stock fell 13.12% on the news. Similar investigations were initiated for JinkoSolar and Stitch Fix.

Pomerantz LLP announced investigations into potential securities fraud at Abeona Therapeutics following disclosure that only 4 of 5 ZEVASKYN treatments were recognized for revenue due to one batch lacking minimum sheet requirements. The stock fell 14.95% to $6.35 on August 13, 2026. Similar investigations were initiated for JinkoSolar and Stitch Fix.